Dunvegan Associates’s iShares Biotechnology ETF IBB Stock Holding History

Dunvegan Associates’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$1.75M	Sell	15,471 -1,038	-6%	-$113K	2.05%	13
2015 Q3	$1.67M	Sell	16,509 -150	-0.9%	-$18K	1.9%	14
2015 Q2	$2.05M	Sell	16,659 -5,973	-26%	-$715K	2.27%	14
2015 Q1	$2.59M	Sell	22,632 -546	-2%	-$60.2K	2.29%	13
2014 Q4	$2.34M	Sell	23,178 -972	-4%	-$94.5K	2.04%	17
2014 Q3	$2.2M	Sell	24,150 -84	-0.3%	-$7.37K	1.99%	17
2014 Q2	$2.08M	Sell	24,234 -237	-1%	-$18.7K	1.73%	19
2014 Q1	$1.93M	Sell	24,471 -3,267	-12%	-$272K	1.62%	22
2013 Q4	$2.1M	Sell	27,738 -6,159	-18%	-$437K	1.73%	19
2013 Q3	$2.37M	Sell	33,897 -1,248	-4%	-$81.8K	1.75%	21
2013 Q2	$2.04M	Buy	+35,145	New	+$2.03M	1.57%	24

Other funds holding IBB

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Dunvegan Associates's IBB Position: Q4 2015 in Review

Dunvegan Associates reduced its iShares Biotechnology ETF (IBB) stake by 6.3% in Q4 2015, selling an estimated $113K and leaving 15,471 shares worth $1.75M. The position accounts for 2.05% of the portfolio, ranked #13.

Dunvegan Associates first reported a position in IBB in Q2 2013 and has held it in 11 quarters since. The position peaked at $2.59M in Q1 2015. 432 funds tracked by Wall St. Rank hold IBB as of Q4 2015.

Dunvegan Associates held 15,471 shares of iShares Biotechnology ETF worth $1.75M as of Q4 2015.
Dunvegan Associates sold 1,038 iShares Biotechnology ETF shares in Q4 2015, an estimated $113K.
iShares Biotechnology ETF made up 2.05% of Dunvegan Associates's portfolio in Q4 2015, its #13 holding.
Dunvegan Associates first reported a position in iShares Biotechnology ETF in Q2 2013 and has held it in 11 quarters since.
Dunvegan Associates's iShares Biotechnology ETF position peaked at $2.59M in Q1 2015.
432 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2015.

Based on Dunvegan Associates's 13F filing for Q4 2015, filed 28 Apr 2017.